For the quarter ending 2026-03-31, RGNX had -$19,237K decrease in cash & cash equivalents over the period. -$77,421K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | -133,711 | - | 140,104 | - |
| Cost of license and royalty revenues | -3,296 | - | 14,370 | - |
| Total research and development expense | -111,349 | - | 168,688 | - |
| Total general and administrative expense | -39,177 | - | 60,483 | - |
| Other segment items | -16,567 | - | 23,292 | - |
| Net income (loss) | -90,051 | -67,149 | -61,941 | -64,788 |
| Stock-based compensation expense | 8,617 | 8,375 | 8,998 | 17,190 |
| Depreciation and amortization | 3,857 | 3,869 | 3,886 | 7,860 |
| Net accretion of discounts on marketable debt securities | 879 | 1,229 | 1,823 | 2,427 |
| Net realized gain on investments | - | 0 | 62 | - |
| Non-cash interest expense | 3,753 | 5,106 | 5,305 | 2,490 |
| Other non-cash adjustments | -19 | -537 | -48 | -12 |
| Accounts receivable | -18,249 | 561 | 6,310 | 790 |
| Prepaid expenses | -384 | -1,016 | 2,167 | 1,709 |
| Other current assets | 1,314 | -6,244 | -7 | 5,593 |
| Operating lease right-of-use assets | -1,705 | -1,664 | -1,683 | -3,306 |
| Other assets | 900 | 345 | 2,389 | -2,121 |
| Accounts payable | 349 | -1,861 | 694 | -1,117 |
| Accrued expenses and other current liabilities | -16,734 | 45 | 2,751 | -2,567 |
| Deferred revenue | -700 | -4,986 | -3,400 | 37,666 |
| Operating lease liabilities | -2,525 | -3,005 | -1,224 | -4,396 |
| Other liabilities | -16 | -10 | -16 | -2,971 |
| Net cash provided by (used in) operating activities | -76,186 | -52,290 | -55,960 | -15,713 |
| Purchases of marketable debt securities | 9,839 | 62,811 | 39,521 | 230,298 |
| Maturities of marketable debt securities | 81,662 | 100,857 | 82,237 | 136,020 |
| Sales of equity securities | - | 0 | 62 | - |
| Purchases of property and equipment | 1,235 | 508 | 491 | 1,415 |
| Net cash provided by investing activities | 70,588 | 37,538 | 42,287 | -95,693 |
| Proceeds from exercise of stock options | 146 | 90 | 0 | 228 |
| Taxes paid related to net settlement of stock-based awards | 828 | 0 | 123 | 510 |
| Proceeds from issuance of common stock under employee stock purchase plan | 648 | 0 | 741 | 307 |
| Offering expenses related to at-the-market offering program | - | - | 75 | 259 |
| Expenses related to at-the-market offering program | 230 | 357 | - | - |
| Proceeds from issuance of royalty bond and warrants, net of transaction costs | - | 0 | -33 | 144,526 |
| Repayments under royalty monetization liabilities, net of interest | 13,375 | 9,651 | 7,593 | 10,854 |
| Net cash used in financing activities | -13,639 | -9,584 | -7,083 | 133,438 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | -19,237 | -24,336 | -20,756 | 22,032 |
| Beginning of period | 36,496 | -1,276 | 59,556 | - |
| End of period | 17,259 | -24,336 | 60,832 | - |
REGENXBIO Inc. (RGNX)
REGENXBIO Inc. (RGNX)